Patient Specific Factors Guiding Treatment Selection in Metastatic Castration Sensitive Prostate Cancer (mCSPC)

In this segment, Dr. Charles J. Ryan asks Dr. Jayram to discuss the patient specific considerations that influence the transition from deciding to intensify therapy to selecting a particular treatment strategy in metastatic castration sensitive prostate cancer (mCSPC). Dr. Jayram explains that treatment selection requires a comprehensive evaluation of each patient’s clinical profile, including age, performance status, comorbid conditions, and concurrent medications. He emphasizes that the presence of cardiovascular disease, metabolic disorders, or other chronic health issues can significantly affect therapy choice and monitoring strategies. The discussion also highlights the importance of considering disease burden, pace of disease progression, and patient preferences when determining the most appropriate treatment approach. Dr. Jayram notes that clinicians must balance clinical evidence with individual patient circumstances to ensure therapy is both effective and tolerable. The segment underscores the growing importance of personalized treatment planning in the modern management of metastatic castration sensitive prostate cancer.